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Implementing the British Thoracic Society’s 
guidelines: the effect of a nurse-run asthma clinic 
on prescribed treatment in an English genera1 
practice 
J. DICKINSON, S. HUTTON AND A. ATKIN 
The advent of computer-based prescribing in general practice has made it possible to study a patient’s drug use in 
detail. This study compared the use of inhaled therapy in 100 patients with chronic disease by examining every 
prescription issued during the year before and the year after initial consultation at a nurse-run asthma clinic. The 
majority were poorly controlled in that 79% scored high on the Jones Morbidity Index at their first visit. 
The number of patients on inhaled corticosteroid and salmeterol xinafoate rose from 87 to 100% and 6 to 28%, 
respectively, while those instructed to take their P-agonist ‘when required ’ as opposed to a regular dose rose from 
26 to 82%. 
The daily median intake of short-acting P-agonist fell from 5.0 to 3.8 doses (P<O.OOOl). 
In the 87 patients on inhaled corticosteroid throughout, the mean daily dose increased from 532.1 to 793.1 ,ug 
(P<O.OOOl), and compliance (defined as the total dose issued in 1 year expressed as a percentage of that 
recommended) increased from 61.5 to 69.3% (P= <O.OS). 
Attendance at a nurse-run asthma clinic was associated with a number of significant alterations in inhaled therapy. 
These changes conformed to the British Thoracic Society’s guidelines. 
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Introduction 
There is now convincing evidence that an inflammatory 
process is present in all grades of asthma severity (1,2). This 
view implies that optimum treatment must reduce and 
maintain the inflammatory cell infiltration to a minimum by 
the avoidance of causal allergies and the early use of 
medications which prevent, or reverse, this process (3). 
Inhaled steroids have proved to be by far the most effective 
agent, both reducing cell infiltration in the airways, and 
improving clinical parameters (4,5). 
As a consequence, the need for bronchodilators should 
be reduced and used only as required (6). Prospective 
studies indicate that chronic P-agonist treatment causes 
some increase in underlying airway responsiveness to non- 
specific and inflammatory challenges (7) and probably a 
degree of tachyphylaxis (8). 
This shift of emphasis from bronchodilators to anti- 
inflammatory treatment has been reflected in the many 
asthma management guidelines published over the last 
few years, including those of the British Thoracic Society 
(9). 
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The successful implementation of this aspect of the 
guidelines in the community should be evident in the 
prescriptions issued to patients who present with poorly 
controlled asthma. The introduction of computer-based 
prescribing in general practice has made such an analysis 
possible. 
This study examines, in detail, prescriptions for inhalers 
issued to patients with significant asthma for 1 year before 
and 1 year after their initial consultation at a general 
practice asthma clinic to see what changes, if any, have been 
made. 
Methods 
The studied seven-partner general practice serves a popula- 
tion of 15 200 patients in a mixed rural and urban area of 
North Lincolnshire, U.K. 
The practice policy for asthma is to target patients with 
more severe problems, first identifying them in a postal 
survey using the Jones Morbidity Index (10). In addition, 
patients are referred to the asthma clinic after hospital 
admission, recent emergency nebulization or if causing 
concern to their general practitioner. 
Four asthma clinics are held each week by two experi- 
enced nurses (SH and AA), both of whom hold the 
National Asthma Training Centre Diploma in asthma 
management, and one (SH) who has completed the advance 
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TABLE 1. A comparison of inhaled steroid, &-agonist use and compliance for 1 year before and 1 year after attendance at a 
nurse-run asthma clinic 
Parameter 
Daily steroid use 
Compliance 
Mean difference 
(post-pre clinic) 
261.Opg 
7~8% 
Median difference 
(post-pre clinic) 
95% 
confidence intervals 
146.2-375.9 
1.34-14.26 
P value 
~0~0001 
co.05 
Test 
t-test 
t test 
Daily &agonist use - 1.2 doses - 2.3- - 0.5 <0~0001 Wilcoxon signed rank test 
course in chronic obstructive lung disease at the Asthma 
Education Centre, Kings Mill Hospital, U.K. 
The general practitioner (JAD) holds concurrent 
surgeries and is available for the assessment of new patients, 
assistance with problems and the signing of prescriptions. 
Patients are allocated 30 min for their first appointment. 
The length of subsequent appointments is dictated by need. 
Stable patients are offered a 15-min appointment at 
6-monthly intervals (occasionally yearly if very mild). 
Treatment strategies follow the 1993 British Thoracic 
Society (BTS) guidelines except for infrequent initiation of 
cromoglycate in children, and a recent tendency to use 
salmeterol xinafoate at moderate, as opposed to high, doses 
of inhaled corticosteroids. The nurses have the authority to 
change devices and both increase and decrease doses of 
inhaled therapy where clinically indicated. The introduction 
of new therapeutic agents is discussed with the doctor. 
Compliance with treatment is facilitated by increasing the 
patients’ knowledge of asthma, allowing time to discuss 
their fears and beliefs, providing educational material and 
the provision of a suitable inhaler device, and the repeated 
checking of its use. Repeat prescriptions are generated by 
computer (MTEC) and archived for future reference. 
The first 100 consecutive patients seen at the clinic who 
had been on preventive therapy (corticosteroids or sodium 
cromoglycate) and short-acting P-agonists for at least 1 year 
prior to their initial asthma clinic appointment were 
included in the study. Print outs of all prescriptions issued 
over the 2 years were examined in detail, noting the types of 
drugs and their strengths, instructions to patients, number 
of devices on each prescription, and the number of doses 
per device. Inhaled corticosteroid dose was expressed as 
units of beclomethasone diproprionate or equivalent. 
Budesonide was considered to be of similar potency (11) 
and fluticasone proprionate twice as potent (12). Com- 
pliance was calculated by expressing the total corticosteroid 
dose issued in 1 year as a percentage of the total dose 
recommended. 
The main outcome measures were the differences between 
the daily dose of D-agonist and inhaled corticosteroid, 
together with compliance for 1 year before and 1 year after 
the initial clinic consultation. The number of patients on 
inhaled corticosteroids, salmeterol zinafoate and ‘as 
needed’ in contrast to regular p-agonist were compared. 
Differences in sample means of daily steroid dose and 
compliance were compared using t-tests. As the data for 
P-agonist use was skewed, the median dose was compared 
using the Wilcoxon signed rank test. 
Results 
The study group consisted of 100 patients (48 male, 52 
female) whose ages ranged from 3 to 79 years (median 36 
years). At their first clinic attendance, 79/100 were classified 
as high morbidity on the Jones Index; and 87, 13, six and 
two were taking inhaled corticosteroids, sodium cromogly- 
cate, salmeterol xinafoate and oral prednisolone, respect- 
ively. Twenty-four patients had been instructed to take 
their P-agonist as needed and 66 on a regular basis. 
One year later, all 100 patients were on inhaled steroids, 
28 on salmeterol zinafoate, one on oral prednisolone and 82 
were instructed to take their P-agonist as needed. Of the 68 
patients who attended for review at 12 months, eight 
(11.7%) were recorded as high morbidity. Thirty-two 
patients defaulted at 1 year, but all were included in the 
study. 
The median daily dose of P-agonist was reduced from 5.0 
to 3.8; a difference of 1.2 (95% confidence interval - 2.3 to 
- 0.5, P<0~0001). 
Of the 87 patients on inhaled steroid throughout, the 
mean daily dose was increased from 532.1 to 793.1 pug; a 
difference of 261 (95% confidence interval 146375.9, 
P<O.OOOl). Compliance increased from 61.5 to 69.3%; a 
difference of 7.8% (95% confidence interval 1.3414.26, 
PcO.05). The results are summarized in Table 1. 
Discussion 
Attendance at a nurse-run asthma clinic was associated 
with a number of significant changes in the prescribing and 
consumption of inhaled therapy. These findings should be 
interpreted with caution as the population studied was 
biased towards patients with high morbidity, and there were 
no controls. 
There was an increase in the number of patients on 
inhaled corticosteroids and long-acting /?-agonists, and a 
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fall in those advised to take ‘regular’ as opposed to ‘as 
needed’ short-acting P-agonists. The mean daily dose of 
inhaled corticosteroids was significantly increased and the 
median daily dose of short-acting p-agonists significantly 
reduced. Compliance with inhaled corticosteroids was 
slightly but significantly improved. 
The overall increase in inhaled corticosteroid together 
with increased prescribing of a long-acting b-agonist 
accords with the step up in treatment recommended in the 
BTS guidelines for managing poorly controlled asthma. 
The fall in short-acting P-agonist use is to be welcomed, but 
patients were still taking in excess of three doses per day, 
many of whom were classified as ‘low morbidity’ on the 
Jones Morbidity Index. Other general practice studies as 
opposed to clinical trials show a similar picture. 
The Grampion Asthma Study of Integrated Care 
(GRASSIC) (13) looked at 712 adult patients attending 
hospital clinics in order to evaluate integrated, as opposed 
to hospital only, care. One of the outcome measures was 
bronchodilator use. Both groups were prescribed around 10 
inhalers per year; that is between five and six doses per day. 
In spite of this, the majority of patients claimed they had 
control of their asthma ‘all of the time’ and most scored 
high on the ‘living with asthma scale’ indicating least 
restriction of activity. Warner (14), in a study of paediatric 
asthma, found the frequency of inhaled salbutamol was 
similar irrespective of the instruction on the prescription, 
and averaged 4-8 puffs day - I. Unlike this study, however, 
those taking higher doses of corticosteroid inhaled more 
P-agonist. 
Experience, therefore, in routine practice as opposed to 
clinical trials shows a similar picture, and the difficulties in 
reducing patients’ dependency on short-acting broncho- 
dilators should not be underestimated. Perhaps patients 
who perceive themselves to be well controlled do so 
by taking regular doses of P-agonist irrespective of the 
instructions on the prescription. 
Alternatively, patients with long-standing asthma may 
have formed the habit of relief inhalation at the slightest 
hint of bronchial constriction. A third possibility is that 
patients have grown to accept a certain amount of disability 
as normal, part of that acceptance being the frequent use of 
relief inhalers. 
Does this matter? The P-agonist debate on the safety 
of regular dosing continues. A recent consensus view 
concluded that there was no convincing evidence that the 
use of bronchodilators was harmful to the lung in the ‘long 
run’, and that when bronchodilators are used in combi- 
nation with anti-inflammatory drugs, the general fear 
amongst patients and doctors about chronic use of these 
drugs was unjustified (15). 
The scrutiny of issued prescriptions is an indirect 
measure of compliance, and the results should be 
interpreted with caution. 
Bearden et al. (16) found a large number of prescriptions 
in general practice were not redeemed, but the authors’ own 
experience as a dispensing practice is that few inhalers are 
uncollected after request and unredeemed prescriptions 
were not a problem. The use of a ‘before and after’ design 
may have nullified the affects of idiosyncratic use such as 
habitual test dosing and duplicate inhalers kept at school or 
work. No patients were obtaining medication from other 
sources such as hospital or outpatients. 
Previous, much larger, studies have looked at prescribing 
costs using data from the Prescription Pricing Authority. 
Jones (17) investigated 59 practices with an interest in 
asthma, and found that although their average prescrib- 
ing costs were lower than their Family Health Service 
Authority average, their respiratory drug costs were higher. 
Naish et al. (18) found that practices approved of 
vocational training, asthma surveillance or band 3 health 
promotion showed a higher level of prophylactic prescrib- 
ing. They also concluded that cost alone is too crude a 
measure of asthma prescribing in general practice, as an 
item is a variable quantity of medication, and the choice 
of drug, and whether it is prescribed generically, would 
influence net ingredient costs. 
Warner (14) reviewed prescribed treatment for children 
with asthma by gathering data from 398 general practices 
using the Compufile-AAH Meditel Computer. This study 
had the merit of large numbers (16 211 children), but 
because of this, was unable to quantify steroid dosage. Six 
or more prescriptions per year were considered sufficient to 
suggest patients were consistently receiving prophylaxis. 
Nearly half the children were prescribed preventive treat- 
ment, and only 15% were judged to be compliant. There are 
limitations in adopting this measure, particularly in adults 
where, for example, a patient taking inhaled budesonide 
400 mcg twice daily via a turbohaler would only have 
sufficient drug for 150 days. 
Patients’ requirements and instructions may fluctuate 
during the course of a year according to the clinical state. 
By careful scrutiny of all prescriptions issued, this study 
took into account changes in both strength and dosage 
advised in the clinic. 
.It is very difficult to decide which aspects of the asthma 
clinic most influenced the sustained changes in inhaled 
therapy. The initial assessment was a joint consultation 
with a Doctor and, in many cases, changes were made 
such as the initiation or increase of inhaled corticosteroid. 
The nurses, however, were responsible for most of any 
subsequent dose alterations, the choice of inhaler device, 
and ensuring instruction was clear and understood. In 
particular, the patients’ beliefs and anxieties about steroid 
therapy were, explored. The present authors agree with 
Cochrane (19)‘that clear consistent advice from all members 
of the team, allied to an educational asthma programme 
and the development of a trusting patient relationship 
should improve compliance. 
Clear evidence of the effectiveness of nurse-run asthma 
clinics is scarce. One recent randomized control trial proved 
inconclusive; the authors, however, described extensive 
methodological problems which made interpretation of 
their results difficult and liable to error (20). The study of 
Charlton et al. (21) did demonstrate beneficial changes in 
outcome, including a reduction in the number of rescue 
doses of systemic steroids. 
For the next few years, it is likely that a reduction in 
asthma morbidity will be achieved by the better use of 
present drugs as well as the introduction of new therapies. 
The application of treatment guidelines remains a major 
challenge to all health professionals. Whilst recognizing 
that compliance with an appropriate drug regime is not the 
only factor involved in the successful management of 
asthma, this study found that patients attending a nurse- 
run general practice clinic showed changes in treatment 
which were in line with British Thoracic Society guidelines. 
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